nephrologylinx Medical News about plasma cell dyscrasias; lenalidomide associated azotemia

Nephrology

Become a Member Today!

Email
Password
Remember me
Forgot your Password?
Invite Code?

Home
General Nephrology

Messages

Conferences

Jobs

Newsletters

My Library

Topics in
Nephrology

Acid-Base

Basic Science/Genetics

Chronic Dz/Renal Failure

Cystic Dz

Dialysis

Economics of Medicine

Endocrinology

Fluids and Electrolytes

Glomerular/Tubular Dz

Hematology/Oncology

Hypertension

Nephropathies

Pediatric Nephrology

Pharmacology/kinetics

Popular Press

Radiology/Diagnostics

Stone Disease

Transplantation

Ureteral Disease

Vascular

Help

Resource Center

RSS News Feeds

Send Newsletter
to a Friend

Sponsor

plasma cell dyscrasias; lenalidomide associated azotemia

Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website

Azotemia associated with use of lenalidomide in plasma cell dyscrasias
Leukemia and Lymphoma, 06/30/08

Email This Article

Save in My Library

Free Abstract

Batts ED et al. - Azotemia is an uncommon, but serious, potential complication of lenalidomide therapy in plasma cell dyscrasias with associated renal insufficiency. Careful monitoring of renal function after initiation of lenalidomide in this setting is advised.

Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT

Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology

Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance

Sponsor